Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients

• DOI: 10.1016/j.nefroe.2024.11.007
• Publication Date: 2024-12-06T12:34:27Z
• Authors: Luis Alberto Vigara; Florentino Villanego; Cristhian Orellana; Myriam Eady; María Gabriela Sá...; Marta Alonso; María Belén García; José Manuel Amaro; Teresa García; Auxiliadora Mazuecos
• Keywords: Trasplante renal; Diabetes mellitus; Riesgo cardiovascular; Obesidad; RC870-923; Agonistas del receptor del péptido 1 similar al glucagón; Diseases of the genitourinary system. Urology; Inmunosupresión

In kidney transplant (KT) recipients diabetes mellitus (DM) are associated with an increased mortality and a poorer graft survival. Glucagon-like peptide 1 receptor agonists (GLP1-RA) have demonstrated cardiovascular renal benefits in the general population. However, there is lacking evidence KT recipients.